Prevalence and characterization of pain in radiation oncology: the PREDORT multicenter cross-sectional study.

IF 2.8 3区 医学 Q2 ONCOLOGY
Clinical & Translational Oncology Pub Date : 2025-02-01 Epub Date: 2024-07-30 DOI:10.1007/s12094-024-03603-4
Fernando Arias, Uxúe Zarandona, Berta Ibáñez-Beróiz, Reyes Ibáñez, Maider Campo, Jon Cacicedo, Noelia García-Rueda, Beatriz Baztán, Raquel Villanueva, Marta Fresán, Iñaki Redín, Ana T Osés, Victoria Hurtado, Inés Villafranca, Vasti Iancu, Pilar Almeida, Nieves Moreno, Soraya Cadena, Irene Carruesco, Marián Allegue, Ana B González
{"title":"Prevalence and characterization of pain in radiation oncology: the PREDORT multicenter cross-sectional study.","authors":"Fernando Arias, Uxúe Zarandona, Berta Ibáñez-Beróiz, Reyes Ibáñez, Maider Campo, Jon Cacicedo, Noelia García-Rueda, Beatriz Baztán, Raquel Villanueva, Marta Fresán, Iñaki Redín, Ana T Osés, Victoria Hurtado, Inés Villafranca, Vasti Iancu, Pilar Almeida, Nieves Moreno, Soraya Cadena, Irene Carruesco, Marián Allegue, Ana B González","doi":"10.1007/s12094-024-03603-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pain in cancer patients has enormous impact on their quality-of-life. Radiation therapy (RT) is a cornerstone in cancer treatment. The objective of the PREDORT study is to estimate the prevalence of pain in patients attending at Radiation Oncology (RO) Services.</p><p><strong>Methods: </strong>A prospective, multicenter study was designed for patients treated at the RO Services of reference hospitals. Patients were seen in their initial Nursing consultation, during which key data was collected, including demographic and comorbidities data, medical history, and oncological and pain characteristics. The study has received approval from the Ethics Committee of Navarra, and all patients signed the Informed Consent.</p><p><strong>Results: </strong>Of the 860 participating patients, 306 reported some type of pain, which implies a prevalence of 35.6%. Of them, 213 identified a cause of oncological origin. The proportion of pain was similar among sexes, but the proportion of non-cancer pain was higher among women (p < 0.05). Regarding pain intensity, the magnitude of breakthrough pain in patients with oncological pain is nearly 1 point greater than in patients with non-oncological pain (7.53 vs 6.81; p = 0.064). Cancer pain is more likely to be limiting of normal life than non-cancer pain (59% versus 38%, p < 0.001). Regarding analgesic treatment, only 60/306 patients (19.6%) were receiving strong opioids. There were 68 patients with pain without any treatment (22.2%).</p><p><strong>Conclusions: </strong>The prevalence of pain in cancer patients referred to RO services is 35.6%, with the prevalence of exclusively oncological pain being 24.8%. Understanding and addressing oncological pain is essential to provide comprehensive care to patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"778-784"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03603-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pain in cancer patients has enormous impact on their quality-of-life. Radiation therapy (RT) is a cornerstone in cancer treatment. The objective of the PREDORT study is to estimate the prevalence of pain in patients attending at Radiation Oncology (RO) Services.

Methods: A prospective, multicenter study was designed for patients treated at the RO Services of reference hospitals. Patients were seen in their initial Nursing consultation, during which key data was collected, including demographic and comorbidities data, medical history, and oncological and pain characteristics. The study has received approval from the Ethics Committee of Navarra, and all patients signed the Informed Consent.

Results: Of the 860 participating patients, 306 reported some type of pain, which implies a prevalence of 35.6%. Of them, 213 identified a cause of oncological origin. The proportion of pain was similar among sexes, but the proportion of non-cancer pain was higher among women (p < 0.05). Regarding pain intensity, the magnitude of breakthrough pain in patients with oncological pain is nearly 1 point greater than in patients with non-oncological pain (7.53 vs 6.81; p = 0.064). Cancer pain is more likely to be limiting of normal life than non-cancer pain (59% versus 38%, p < 0.001). Regarding analgesic treatment, only 60/306 patients (19.6%) were receiving strong opioids. There were 68 patients with pain without any treatment (22.2%).

Conclusions: The prevalence of pain in cancer patients referred to RO services is 35.6%, with the prevalence of exclusively oncological pain being 24.8%. Understanding and addressing oncological pain is essential to provide comprehensive care to patients.

放射肿瘤科疼痛的发生率和特征:PREDORT 多中心横断面研究。
背景:癌症患者的疼痛对其生活质量影响巨大。放射治疗(RT)是癌症治疗的基石。PREDORT 研究的目的是估计在放射肿瘤学(RO)服务处就诊的患者的疼痛发生率:方法:针对在参考医院放射肿瘤科接受治疗的患者设计了一项前瞻性多中心研究。患者在首次护理咨询时就诊,在此期间收集关键数据,包括人口统计学和合并症数据、病史、肿瘤和疼痛特征。该研究已获得纳瓦拉伦理委员会的批准,所有患者均签署了知情同意书:在 860 名参与研究的患者中,有 306 人报告了某种类型的疼痛,患病率为 35.6%。其中,213 人的病因与肿瘤有关。男女患者的疼痛比例相似,但女性患者的非癌症疼痛比例更高(P转诊到区域医疗服务机构的癌症患者中,疼痛发生率为 35.6%,其中 24.8%的疼痛完全是肿瘤引起的。要为患者提供全面的护理,了解并解决肿瘤疼痛问题至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
2.90%
发文量
240
审稿时长
1 months
期刊介绍: Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信